

Simbec-Orion and Avance Clinical Forge Strategic Partnership to Expand Global CRO Capabilities

February 26, 2025 | News | By Ankit Kankar | ankit.kankar@mmactiv.com

The collaboration unites two agile, full-service CROs to deliver seamless, high-quality clinical trial solutions across Europe, the UK, Australia, Asia, and North America, enhancing global access for biotech and pharmaceutical companies.



This formal agreement establishes a collaborative framework between two like-minded, full-service Contract Research Organizations (CROs), united by their shared commitment to high-quality, agile service delivery. Together, the partnership offers a seamless, globally integrated solution for clinical trial execution, enabling biotech and pharmaceutical companies to access unparalleled expertise and resources worldwide.

Both Simbec-Orion and Avance Clinical provide comprehensive clinical research services spanning First in Human (Healthy Volunteers and patients) to pivotal Phase III studies. These include Project Management, Clinical Operations, Medical Monitoring, Regulatory Affairs, Data Management, Biostatistics, Quality Assurance, Pharmacovigilance in addition to IMP Management, Central Lab Services. By leveraging their combined capabilities and complementary regional strengths, the partnership delivers greater access to key patient populations and ensures a single, cohesive CRO experience for clients navigating complex clinical development programs.

“We regard Simbec-Orion as a high-quality CRO, and our partnership allows Avance Clinical to collaborate with clinical sites across Europe and the UK for executing global clinical trials on behalf of our clients. This collaboration enhances our already robust capabilities in [Australia](#), [Asia](#), and the US,” said Yvonne Lungershausen, CEO of Avance Clinical.

“This partnership exemplifies the synergy between two agile, full-service CROs with a shared commitment to delivering tailored, high-quality clinical trial solutions. Together, we’re poised to provide clients with a seamless, fully integrated approach to global clinical development,” said Fabrice Chartier, CEO of Simbec-Orion.

Simbec-Orion, headquartered in the UK, has almost 50 years of experience and operates across 34 countries in the UK, Europe, the United States, Canada and Asia-Pacific. The signing of this MOU considerably expands activities in the Asia-Pacific region. Renowned for its tailored and scalable solutions, and with facilities which include a purpose-built MHRA Accredited [Phase I](#) Unit in the UK, the organization specializes in Clinical Pharmacology, Oncology, and Rare Diseases. Support for clients can begin while they are still at the nonclinical stage, with consultancy which enables a smooth transition into the clinical phase. Simbec-Orion's adaptive approach, supported by highly experienced teams and deep therapeutic expertise, ensures efficient, high-quality clinical trial delivery.

Avance Clinical, the largest premium full-service Australian-headquartered CRO, provides quality clinical trials with globally accepted data across [Australia](#), New Zealand, [Asia](#), [North America](#), and Europe through this partnership. With over 30 years of experience and a proven track record across 250+ indications, Avance Clinical supports clients from pre-clinical consulting through to Phase I-III trials, consistently delivering data that meets FDA and EMA standards.

The partnership enables both organizations to seamlessly execute global clinical trials as a unified entity. By combining their agile cultures and expertise, Simbec-Orion and Avance Clinical deliver faster, more efficient trial outcomes without compromising on quality. This collaboration enhances Avance Clinical's capabilities in Europe and the UK while extending Simbec-Orion's reach into [Australia](#) and [Asia](#).